[HTML][HTML] PCSK9 inhibitors: a new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
PCSK9 inhibitors: clinical evidence and implementation
MS Sabatine - Nature reviews cardiology, 2019 - nature.com
The gene encoding PCSK9 was first identified and linked to the phenotype of familial
hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role …
hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role …
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
MJ Chapman, JK Stock, HN Ginsberg - Current opinion in …, 2015 - journals.lww.com
PCSK9 inhibitors and cardiovascular disease: heralding a new... : Current Opinion in
Lipidology PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era …
Lipidology PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era …
PCSK9 inhibitors for treating hypercholesterolemia
A Pasta, AL Cremonini, L Pisciotta… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering
treatments has established that treatments aiming to lower low-density lipoprotein …
treatments has established that treatments aiming to lower low-density lipoprotein …
Statins and PCSK9 inhibitors: A new lipid-lowering therapy
E Gallego-Colon, A Daum, C Yosefy - European journal of pharmacology, 2020 - Elsevier
The clinical benefit of lipid-lowering therapies is to reduce circulating levels of atherogenic
particles and to ameliorate the risk of atherosclerotic cardiovascular disease (ASCVD). The …
particles and to ameliorate the risk of atherosclerotic cardiovascular disease (ASCVD). The …
Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs
BM Everett, RJ Smith, WR Hiatt - New England Journal of …, 2015 - Mass Medical Soc
Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes
CN Hess, CC Low Wang, WR Hiatt - Annual review of medicine, 2018 - annualreviews.org
Atherosclerotic cardiovascular disease (ASCVD) is associated with significant morbidity and
mortality worldwide. Increased serum levels of low-density lipoprotein cholesterol (LDL-C) …
mortality worldwide. Increased serum levels of low-density lipoprotein cholesterol (LDL-C) …
Lipid lowering with PCSK9 inhibitors
RT Dadu, CM Ballantyne - Nature Reviews Cardiology, 2014 - nature.com
Statins are the most-effective therapy currently available for lowering the LDL-cholesterol
(LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for …
(LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for …
[HTML][HTML] PCSK9 inhibitors in clinical practice: delivering on the promise?
RM Stoekenbroek, ML Hartgers, R Rutte, DD de Wijer… - Atherosclerosis, 2018 - Elsevier
Background and aims In clinical trials, protein convertase subtilisin/kexin type 9 (PCSK9)
inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and …
inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and …
[HTML][HTML] PCSK9: From discovery to therapeutic applications
M Farnier - Archives of cardiovascular diseases, 2014 - Elsevier
The proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism
mainly by targeting the low-density lipoprotein receptor (LDLR) for degradation in the liver …
mainly by targeting the low-density lipoprotein receptor (LDLR) for degradation in the liver …